Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of donidalorsen in hereditary angioedema
NL-OMON59059Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Oct 2020
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of donidalorsen in hereditary angioedema (HAE), sponsored by Ionis Pharmaceuticals. Primary endpoint: Percentage of participants with at least one treatment-emergent adverse event. Started Oct 2020; status: completed.
02
Drugs
donidalorsen
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NL-OMON59059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59059.